Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis

Launched by HAMAD MEDICAL CORPORATION · May 1, 2018

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called dexamethasone can help prevent a second wave of allergic reactions, known as biphasic anaphylaxis, in children who have already experienced an allergic reaction. Anaphylaxis is a serious and potentially life-threatening allergic reaction that can affect multiple organs in the body. The researchers want to see if giving dexamethasone, in addition to standard treatment like adrenaline, can reduce the chances of patients experiencing these delayed reactions.

Children between 3 months and 14 years old who come to the Pediatric Emergency Department with mild to moderate anaphylaxis may be eligible to participate. Participants will be randomly assigned to receive either dexamethasone or a placebo (a dummy treatment) after they are stabilized. They will be monitored closely during their stay, and once they are feeling better, they will go home with an antihistamine to take for five days. The researchers will follow up with a phone call a week later to check on how the children are doing and if they have experienced any return of symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients 3 monthes-14years presenting to the Pediatric Emergency Department (AlSadd) with mild to moderate anaphylaxis
• Exclusion Criteria:
• • Patients with severe anaphylaxis. Patient with history of immunological diseases. Patients on steroids therapy Patient with moderate-severe asthma on medication Patients with severe asthma